Clinical Trial Update: Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the safety and efficacy of FURESTEM-AD Inj. in adults with moderate to severe chronic atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• FURESTEM-AD Inj.

Snippet

Sponsor: Kang Stem Biotech Co., Ltd. | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED